Full metadata record
DC Field | Value | Language |
---|---|---|
dc.creator | Roncal, C. (Carmen) | - |
dc.creator | Orbe, J. (Josune) | - |
dc.creator | Belzunce, M. (Miriam) | - |
dc.creator | Rodriguez, J.A. (José Antonio) | - |
dc.creator | Paramo, J.A. (José Antonio) | - |
dc.date.accessioned | 2012-05-28T15:17:41Z | - |
dc.date.available | 2012-05-28T15:17:41Z | - |
dc.date.issued | 2006 | - |
dc.identifier.citation | Roncal C, Orbe J, Belzunce M, Rodriguez JA, Paramo JA. The 4G/5G PAI-1 polymorphism influences the endothelial response to IL-1 and the modulatory effect of pravastatin. J Thromb Haemost 2006 Aug;4(8):1798-1803. | es_ES |
dc.identifier.issn | 1538-7836 | - |
dc.identifier.uri | https://hdl.handle.net/10171/22248 | - |
dc.description.abstract | BACKGROUND: Increased plasminogen activator inhibitor (PAI-1) levels lead to impaired fibrinolytic function associated with higher cardiovascular risk. PAI-1 expression may be regulated by different inflammatory cytokines such as interleukin-1alpha (IL-1). Several polymorphisms have been described in the PAI-1 gene. AIM: We examined the influence of the 4G/5G polymorphism in the promoter region on IL-1alpha-induced PAI-1 expression by human umbilical vein endothelial cells (HUVEC) in presence or absence of pravastatin. METHODS AND RESULTS: Genotyped HUVEC were incubated with IL-1alpha (500 U mL(-1)) in presence or absence of pravastatin (1-10 microm). PAI-1 expression was analyzed by real time polymerase chain reaction (PCR), and PAI-1 antigen measured in supernatants by ELISA. IL-1alpha increased PAI-1 secretion in a genotype-dependent manner, and higher values were observed for 4G/4G compared with both 4G/5G and 5G/5G cultures (P < 0.05). Preincubation of HUVEC with 10 microm pravastatin significantly reduced IL-1-induced PAI-1 expression in 4G/4G HUVEC compared with untreated cultures (177.5% +/- 24.5% vs. 257.9% +/- 39.0%, P < 0.05). Pravastatin also attenuated the amount of secreted PAI-1 by 4G/4G HUVEC after IL-1 stimulation (5020.6 +/- 165.7 ng mL(-1) vs. 4261.1 +/- 309.8 ng mL(-1), P < 0.05). This effect was prevented by coincubation with mevalonate, indicating a dependence on HMG-CoA reductase inhibition. CONCLUSIONS: The endothelial 4G/5G PAI-1 genotype influences the PAI-1 response to IL-1alpha and the modulatory effect of pravastatin. As increased PAI-1 levels have been linked to cardiovascular disease the observed endothelial modulation by pravastatin may have potential clinical implications. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Wiley-Blackwell | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.subject | Fibrinolysis | es_ES |
dc.subject | Interleukin-1 | es_ES |
dc.subject | Plasminogen activator inhibitor-1 | es_ES |
dc.subject | Polymorphism | es_ES |
dc.subject | Pravastatin | es_ES |
dc.title | The 4G/5G PAI-1 polymorphism influences the endothelial response to IL-1 and the modulatory effect of pravastatin | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.relation.publisherversion | http://bit.ly/LfWwiJ | es_ES |
dc.type.driver | info:eu-repo/semantics/article | es_ES |
Files in This Item:
Statistics and impact
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.